Study of Olverembatinib (HQP1351) in Patients With CML-CP
Trial details
- Registry ID
- NCT06423911
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Olverembatinib (HQP1351) in Patients With CML-CPNCT06423911 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2027-06-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |